SCHEMBL19853313

SCHEMBL19853313

COC(=O)[C@@H]1C[C@@H](C(=O)OC)N(C(=O)OC(C)(C)C)C1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.43
ANPEP P15144 2/20 0.43
NR1H2 P55055 2/20 0.41
NR1H3 Q13133 1/20 0.41
PTPN1 P18031 1/20 0.41
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
BRD4 O60885 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HTRA1 Q92743 1/20 0.38
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
ALDH1A1 P00352 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
P2RX3 P56373 1/20 0.36
PDE4B Q07343 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6122335 1.00 MMP2 (0.43) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL6122332 1.00 MMP2 (0.43) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL17706791 0.95 MMP2 (0.39) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL17343499 0.95 MMP2 (0.39) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL20212525 0.91 HSD17B10 (0.42) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL6121804 0.91 HSD17B10 (0.45) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL21430191 0.91 HSD17B10 (0.45) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL21527750 0.91 HSD17B10 (0.45) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL10592282 0.91 HSD17B10 (0.42) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL6186427 0.91 HSD17B10 (0.45) MMP2ANPEPNR1H2NR1H3PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3490994-B1 SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2024-02-07 EP disclosed
CN-109661398-B Spiro-lactam and di-spiro-lactam NMDA receptor modulators and uses thereof 阿普廷伊克斯股份有限公司 2022-07-05 CN disclosed
US-20220098211-A1 SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC. 2022-03-31 US disclosed
US-11028095-B2 Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2021-06-08 US disclosed
US-20200181159-A1 SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2020-06-11 US disclosed
WO-2018026792-A1 SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC. (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200181159-A1 SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN2C MMP2 2482/4885ANPEP 2983/4885NR1H2 394/4885
US-20220098211-A1 SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN2C MMP2 2482/4885ANPEP 2983/4885NR1H2 394/4885
US-11028095-B2 Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN2C MMP2 2482/4885ANPEP 2983/4885NR1H2 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.